Harvard Bioscience develops, manufactures and sells technologies, products and services that enable fundamental develops in life science applications. Co.'s product families are cellular and molecular technology (CMT) and Preclinical. Co.'s CMT product family includes products supporting research related to molecular, cellular organ and organoid technologies, with additional application in the field of bio-production of pharmaceuticals and therapeutics. Co.'s Preclinical product family includes business lines that support the preclinical research and testing phase for drug development, and in particular testing related to data collection and analysis for safety and regulatory compliance. The HBIO YTD return is shown above.
The YTD Return on the HBIO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether HBIO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HBIO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|